The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy

[1]  K. Jöckel,et al.  Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Nichol,et al.  EGFR mutation status on brain metastases from non-small cell lung cancer. , 2016, Lung cancer.

[3]  P. Allavena,et al.  Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  S. Demaria,et al.  Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking? , 2016, Journal of Immunotherapy for Cancer.

[5]  A. Khalil,et al.  Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2′‐deoxy‐2′‐[18F] fluoro‐D‐glucose‐PET/CT scans to predict survival early during treatment of locally advanced non‐small cell lung cancer (NSCLC) , 2016, Journal of medical imaging and radiation oncology.

[6]  P. Graziano,et al.  Diagnostic Performance of (18)F-Fluorodeoxyglucose in 162 Small Pulmonary Nodules Incidentally Detected in Subjects Without a History of Malignancy. , 2016, The Annals of thoracic surgery.

[7]  R. Fietkau,et al.  Neoadjuvante Radiochemotherapie gefolgt von kurativer Resektion im fortgeschrittenen Stadium IIIA/IIIB eines nicht kleinzelligen Lungenkarzinoms: prognostische Faktoren und Ergebnisse , 2016, Zentralblatt für Chirurgie.

[8]  G. Persson,et al.  Early lesion-specific (18)F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  R. Rami-Porta,et al.  Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunities. , 2015, Translational lung cancer research.

[10]  A. Niemierko,et al.  Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. , 2015, Neuro-oncology.

[11]  Eric J. W. Visser,et al.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  A. Sapino,et al.  Primary systemic treatment and concomitant low dose radiotherapy for breast cancer: final results of a prospective phase II study. , 2014, Breast.

[13]  P. Philip,et al.  Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  E. Smit,et al.  Trimodality therapy for stage IIIA non-small cell lung cancer: benchmarking multi-disciplinary team decision-making and function. , 2014, Lung cancer.

[15]  Qiyong Ding,et al.  PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST). , 2014, Journal of thoracic disease.

[16]  G. Maira,et al.  Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma , 2014, Strahlentherapie und Onkologie.

[17]  L. Indovina,et al.  A prospective analysis of 18F-FDG PET/CT in patients with uveal melanoma: comparison between metabolic rate of glucose (MRglu) and standardized uptake value (SUV) and correlations with histopathological features , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  A. Alavi,et al.  SUVmax of 2.5 should not be embraced as a magic threshold for separating benign from malignant lesions , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  G. Scagliotti,et al.  Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography. , 2013, Clinical lung cancer.

[20]  G. Michaud,et al.  Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[21]  Alessandro Brunelli,et al.  Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[22]  V. Valentini,et al.  Low-dose radiotherapy as a chemo-potentiator of a chemotherapy regimen with pemetrexed for recurrent non-small-cell lung cancer: a prospective phase II study. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  L. Bonomo,et al.  MRI evaluation of neoadjuvant low-dose fractionated radiotherapy with concurrent chemotherapy in patients with locally advanced breast cancer. , 2012, The British journal of radiology.

[24]  L. Tanoue,et al.  Lung cancer: epidemiology, etiology, and prevention. , 2011, Clinics in chest medicine.

[25]  M. Mohiuddin,et al.  Low-Dose Fractionated Radiation Potentiates the Effects of Cisplatin Independent of the Hyper-Radiation Sensitivity in Human Lung Cancer Cells , 2011, Molecular Cancer Therapeutics.

[26]  K. Kerr,et al.  Guidelines on the radical management of patients with lung cancer , 2010, Thorax.

[27]  E. Felip,et al.  Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  Jose Belderbos,et al.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D. Lacombe,et al.  EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  J. Welsh,et al.  Pattern of failure following chemoradiation for locally advanced non-small cell lung cancer: potential role for stereotactic body radiotherapy. , 2010, Anticancer research.

[31]  V. Valentini,et al.  Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings? , 2010, International journal of radiation oncology, biology, physics.

[32]  W. Curran,et al.  Final Report of a Pilot Study of Carboplatin Plus Dose Dense Pemetrexed and Radiotherapy for Locally-advanced Non–small-cell Lung Carcinoma , 2009 .

[33]  V. Rusch,et al.  Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial , 2009, The Lancet.

[34]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[35]  J. Crowley,et al.  The revised TNM staging system for lung cancer. , 2009, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[36]  B. Neyns,et al.  Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). , 2008, Lung cancer.

[37]  David W Townsend,et al.  Time Course of Early Response to Chemotherapy in Non–Small Cell Lung Cancer Patients with 18F-FDG PET/CT , 2007, Journal of Nuclear Medicine.

[38]  Matthias Reimold,et al.  18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[39]  T. Naruke,et al.  Prognostic significance of [18F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma , 2006, Cancer.

[40]  Otto S Hoekstra,et al.  Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  T. Manabe,et al.  [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. , 2005, Neoplasia.

[42]  T. Naruke,et al.  Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. , 2004, Lung cancer.

[43]  W. Regine,et al.  Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm. , 2004, International journal of radiation oncology, biology, physics.

[44]  Danny Rischin,et al.  Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  W. Regine,et al.  Low-dose fractionated radiation potentiates the effects of Paclitaxel in wild-type and mutant p53 head and neck tumor cell lines. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  D. Wood,et al.  Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  F. Foppiano,et al.  Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer , 1999, British Journal of Cancer.

[48]  H. Tonami,et al.  Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[49]  V J Lowe,et al.  Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. , 1995, The Annals of thoracic surgery.

[50]  R L Wahl,et al.  Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[51]  D. Naidich,et al.  Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2017 .

[52]  R. Fietkau,et al.  [Neoadjuvant Radiochemotherapy Followed by Curative Resection in Patients with Advanced Non-Small Cell Lung Cancer in Stage IIIA/IIIB: Prognostic Factors and Results]. , 2016, Zentralblatt fur Chirurgie.

[53]  K. Hirata,et al.  The Diagnosis and Treatment of Lung Cancer , 2014 .

[54]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[55]  W. Oyen,et al.  Biological correlates of FDG uptake in non-small cell lung cancer. , 2007, Lung cancer.

[56]  T. Naruke,et al.  Prognostic significance of [18F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma , 2006, Cancer.

[57]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[58]  P C Goodman,et al.  Evaluation of primary pulmonary carcinoid tumors using FDG PET. , 1998, AJR. American journal of roentgenology.